首页> 外文期刊>Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research >Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biologic disease-modifying antirheumatic drugs (vol 75, pg 1293, 2016)

【24h】

Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biologic disease-modifying antirheumatic drugs (vol 75, pg 1293, 2016)

机译：对常规合成或生物疾病改性抗腹性药物不充分应对（Vol 75，PG 1293,2016）后，Tofacitinib的疗效和安全性

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research》 |2017年第3期|共1页
作者
Charles-Schoeman C.; Burmester G.; Nash P.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类免疫性疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biologic disease-modifying antirheumatic drugs (vol 75, pg 1293, 2016) [J] . Charles-Schoeman C., Burmester G., Nash P. Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2017,第3期

机译：对常规合成或生物疾病改性抗腹性药物不充分应对（Vol 75，PG 1293,2016）后，Tofacitinib的疗效和安全性
2. Original article: Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs [J] . Vibeke Strand, Kurt de Vlam, Jose A Covarrubias-Cobos, RMD Open . 2019,第1期

机译：原始文章：Tofacitinib或阿达木单抗与安慰剂：OPAL病人加宽的患者报告结局-一项对传统合成疾病抗风湿药反应不足的活动性银屑病关节炎的III期研究
3. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis. [J] . Salliot C, Finckh A, Katchamart W, Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2011,第2期

机译：生物抗风湿药在类风湿关节炎中对常规疾病缓解性抗风湿药或抗肿瘤坏死因子药物反应不足的患者的间接比较：一项荟萃分析。
4. Extended report: Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs [O] . Christina Charles-Schoeman, Gerd Burmester, Peter Nash, -1

机译：扩展报告：托法替尼对常规合成或可改变疾病的抗风湿药反应不足后的疗效和安全性
5. Erratum: Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biologic diseasemodifying antirheumatic drugs [O] . 2017

机译：误诊：TOFACITINIB对常规合成或生物脱消药物的反应不足之后的疗效和安全性

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号